About the Leendert Trouw Group

We study complement and (auto)antibodies as fundamental research and as translational research regarding the development of biomarkers and novel therapeutics. The work is performed in three major themes:

  1. The role of complement in the break of tolerance against post-translationally modified proteins
  2. The development of novel bi-specific antibodies to inhibit or enhance complement activation
  3. The circulating levels and biology of complement proteins in health and disease

 

The work of these three major themes is aimed to understand the role of complement and (auto)antibodies in human disease and in current therapy. By understanding the role of complement in the formation of anti-post-translationally modified protein responses we aim to intervene in this process to block autoimmunity. At the same time we want to use the information to boost desired immune responses e.g. against infection and cancer. The knowledge on complement and specific autoantibodies will be utilized to generate new bi-specific antibodies engineered to have optimal properties to act locally to enhance or block complement activity. The knowledge obtained from the complement biology theme will not only allow biomarker discovery for personalized medicine, but will also enable to optimal use of complement for the proposed therapeutic antibodies. All three themes span the full spectrum from in vitro protein chemistry to in vivo experimental models and human subjects.

Collaborate with us

Looking for information on one of our topics, a new place to conduct your research or connect to experienced researchers to join forces with?  Feel free to contact us!

Read more